Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer

Shazli N. Malik, Michael Brattain, Paramita M. Ghosh, Dean A. Troyer, Thomas Prihoda, Roble Bedolla, Jeffrey I. Kreisberg

Research output: Contribution to journalArticle

277 Citations (Scopus)

Abstract

Purpose: Whereas the early stage of prostate cancer is marked by excessive proliferation, in advanced stages of the disease, a decreased apoptotic death rate (increased cell survival) also contributes to net tumor growth. Altered regulation of the mitogen-activated protein kinase (MAPK)-regulated cell proliferation and Akt-regulated cell survival pathways are suspected causes. In this study, we wanted to determine: (a) whether the degree of Akt activation can be assessed by immunohistochemical staining of paraffin-embedded human prostate cancer biopsies with an antibody to phospho-Akt (Ser473); and (b) whether phospho-MAPK/Erk1/2 and phospho-Akt expression are altered in prostate cancer. Experimental design: To examine the activation status of MAPK/Erk1/2 and Akt, archival paraffin-embedded sections from 74 cases of resected prostate cancer were immunostained with antibodies to phospho-MAPK/Erk1/2 (Thr202/Tyr204) and phospho-Akt (Ser473). Results: The staining intensity for phospho-Akt was significantly greater in Gleason grades 8-10 (92% of such cases staining strongly) compared with prostatic intraepithelial neoplasia and all other grades of prostate cancer (only 10% of these cases staining strongly; P ≤ 0.001). The staining intensity for phospho-MAPK/Erk, on the other hand, was significantly greater for normal, hyperplastic, and prostatic intraepithelial neoplasia lesions but declined with disease progression, reaching its lowest level of expression in high Gleason grades 8-10 (P < 0.0001). Conclusion: The activation state of the cell survival protein Akt can be analyzed in human prostate cancer by immunohistochemical staining of paraffin-embedded tissue with a phospho-specific Akt (Ser473) antibody. Advanced disease is accompanied by activation of Akt and inactivation of Erk.

Original languageEnglish (US)
Pages (from-to)1168-1171
Number of pages4
JournalClinical Cancer Research
Volume8
Issue number4
StatePublished - Apr 1 2002

Fingerprint

Prostatic Neoplasms
Staining and Labeling
Mitogen-Activated Protein Kinase 1
Paraffin
Prostatic Intraepithelial Neoplasia
Cell Survival
Mitogen-Activated Protein Kinases
Antibodies
Disease Progression
Research Design
Cell Proliferation
Biopsy
Mortality
Growth
Neoplasms
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Malik, S. N., Brattain, M., Ghosh, P. M., Troyer, D. A., Prihoda, T., Bedolla, R., & Kreisberg, J. I. (2002). Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer. Clinical Cancer Research, 8(4), 1168-1171.

Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer. / Malik, Shazli N.; Brattain, Michael; Ghosh, Paramita M.; Troyer, Dean A.; Prihoda, Thomas; Bedolla, Roble; Kreisberg, Jeffrey I.

In: Clinical Cancer Research, Vol. 8, No. 4, 01.04.2002, p. 1168-1171.

Research output: Contribution to journalArticle

Malik, SN, Brattain, M, Ghosh, PM, Troyer, DA, Prihoda, T, Bedolla, R & Kreisberg, JI 2002, 'Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer', Clinical Cancer Research, vol. 8, no. 4, pp. 1168-1171.
Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al. Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer. Clinical Cancer Research. 2002 Apr 1;8(4):1168-1171.
Malik, Shazli N. ; Brattain, Michael ; Ghosh, Paramita M. ; Troyer, Dean A. ; Prihoda, Thomas ; Bedolla, Roble ; Kreisberg, Jeffrey I. / Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 4. pp. 1168-1171.
@article{a1fdfd8838914be781cb37af1589dfaf,
title = "Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer",
abstract = "Purpose: Whereas the early stage of prostate cancer is marked by excessive proliferation, in advanced stages of the disease, a decreased apoptotic death rate (increased cell survival) also contributes to net tumor growth. Altered regulation of the mitogen-activated protein kinase (MAPK)-regulated cell proliferation and Akt-regulated cell survival pathways are suspected causes. In this study, we wanted to determine: (a) whether the degree of Akt activation can be assessed by immunohistochemical staining of paraffin-embedded human prostate cancer biopsies with an antibody to phospho-Akt (Ser473); and (b) whether phospho-MAPK/Erk1/2 and phospho-Akt expression are altered in prostate cancer. Experimental design: To examine the activation status of MAPK/Erk1/2 and Akt, archival paraffin-embedded sections from 74 cases of resected prostate cancer were immunostained with antibodies to phospho-MAPK/Erk1/2 (Thr202/Tyr204) and phospho-Akt (Ser473). Results: The staining intensity for phospho-Akt was significantly greater in Gleason grades 8-10 (92{\%} of such cases staining strongly) compared with prostatic intraepithelial neoplasia and all other grades of prostate cancer (only 10{\%} of these cases staining strongly; P ≤ 0.001). The staining intensity for phospho-MAPK/Erk, on the other hand, was significantly greater for normal, hyperplastic, and prostatic intraepithelial neoplasia lesions but declined with disease progression, reaching its lowest level of expression in high Gleason grades 8-10 (P < 0.0001). Conclusion: The activation state of the cell survival protein Akt can be analyzed in human prostate cancer by immunohistochemical staining of paraffin-embedded tissue with a phospho-specific Akt (Ser473) antibody. Advanced disease is accompanied by activation of Akt and inactivation of Erk.",
author = "Malik, {Shazli N.} and Michael Brattain and Ghosh, {Paramita M.} and Troyer, {Dean A.} and Thomas Prihoda and Roble Bedolla and Kreisberg, {Jeffrey I.}",
year = "2002",
month = "4",
day = "1",
language = "English (US)",
volume = "8",
pages = "1168--1171",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer

AU - Malik, Shazli N.

AU - Brattain, Michael

AU - Ghosh, Paramita M.

AU - Troyer, Dean A.

AU - Prihoda, Thomas

AU - Bedolla, Roble

AU - Kreisberg, Jeffrey I.

PY - 2002/4/1

Y1 - 2002/4/1

N2 - Purpose: Whereas the early stage of prostate cancer is marked by excessive proliferation, in advanced stages of the disease, a decreased apoptotic death rate (increased cell survival) also contributes to net tumor growth. Altered regulation of the mitogen-activated protein kinase (MAPK)-regulated cell proliferation and Akt-regulated cell survival pathways are suspected causes. In this study, we wanted to determine: (a) whether the degree of Akt activation can be assessed by immunohistochemical staining of paraffin-embedded human prostate cancer biopsies with an antibody to phospho-Akt (Ser473); and (b) whether phospho-MAPK/Erk1/2 and phospho-Akt expression are altered in prostate cancer. Experimental design: To examine the activation status of MAPK/Erk1/2 and Akt, archival paraffin-embedded sections from 74 cases of resected prostate cancer were immunostained with antibodies to phospho-MAPK/Erk1/2 (Thr202/Tyr204) and phospho-Akt (Ser473). Results: The staining intensity for phospho-Akt was significantly greater in Gleason grades 8-10 (92% of such cases staining strongly) compared with prostatic intraepithelial neoplasia and all other grades of prostate cancer (only 10% of these cases staining strongly; P ≤ 0.001). The staining intensity for phospho-MAPK/Erk, on the other hand, was significantly greater for normal, hyperplastic, and prostatic intraepithelial neoplasia lesions but declined with disease progression, reaching its lowest level of expression in high Gleason grades 8-10 (P < 0.0001). Conclusion: The activation state of the cell survival protein Akt can be analyzed in human prostate cancer by immunohistochemical staining of paraffin-embedded tissue with a phospho-specific Akt (Ser473) antibody. Advanced disease is accompanied by activation of Akt and inactivation of Erk.

AB - Purpose: Whereas the early stage of prostate cancer is marked by excessive proliferation, in advanced stages of the disease, a decreased apoptotic death rate (increased cell survival) also contributes to net tumor growth. Altered regulation of the mitogen-activated protein kinase (MAPK)-regulated cell proliferation and Akt-regulated cell survival pathways are suspected causes. In this study, we wanted to determine: (a) whether the degree of Akt activation can be assessed by immunohistochemical staining of paraffin-embedded human prostate cancer biopsies with an antibody to phospho-Akt (Ser473); and (b) whether phospho-MAPK/Erk1/2 and phospho-Akt expression are altered in prostate cancer. Experimental design: To examine the activation status of MAPK/Erk1/2 and Akt, archival paraffin-embedded sections from 74 cases of resected prostate cancer were immunostained with antibodies to phospho-MAPK/Erk1/2 (Thr202/Tyr204) and phospho-Akt (Ser473). Results: The staining intensity for phospho-Akt was significantly greater in Gleason grades 8-10 (92% of such cases staining strongly) compared with prostatic intraepithelial neoplasia and all other grades of prostate cancer (only 10% of these cases staining strongly; P ≤ 0.001). The staining intensity for phospho-MAPK/Erk, on the other hand, was significantly greater for normal, hyperplastic, and prostatic intraepithelial neoplasia lesions but declined with disease progression, reaching its lowest level of expression in high Gleason grades 8-10 (P < 0.0001). Conclusion: The activation state of the cell survival protein Akt can be analyzed in human prostate cancer by immunohistochemical staining of paraffin-embedded tissue with a phospho-specific Akt (Ser473) antibody. Advanced disease is accompanied by activation of Akt and inactivation of Erk.

UR - http://www.scopus.com/inward/record.url?scp=0036554734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036554734&partnerID=8YFLogxK

M3 - Article

C2 - 11948129

AN - SCOPUS:0036554734

VL - 8

SP - 1168

EP - 1171

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -